Sanofi: Credit Suisse still rates 'Outperform'
(CercleFinance.com) - Credit Suisse reiterates its "outperform" rating on the Sanofi share, along with its target price of 105 euros, following an oncology R&D conference by the French healthcare giant at ASCO 2020.
"Sanofi remains a top pick in the sector based on current low valuation and an expected improvement in returns as new management focusses both R&D and marketing resources better," the broker says.
It adds that "Growth from both Dupixent and vaccines over the next few years should give management time to effect that transition".
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.